Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic viru

Abstract

Interferons are circulating factors that bind to cell surface receptors, activating a signaling cascade, ultimately leading to both an antiviral response and an induction of growth inhibitory and/or apoptotic signals in normal and tumor cells1. Attempts to exploit the ability of interferons to limit the growth of tumors in patients has met with limited results2 because of cancer-specific mutations of gene products in the interferon pathway3,4,5,6,7. Although interferon-non-responsive cancer cells may have acquired a growth/survival advantage over their normal counterparts, they may have simultaneously compromised their antiviral response. To test this, we used vesicular stomatitis virus (VSV), an enveloped, negative-sense RNA virus8 exquisitely sensitive to treatment with interferon9. VSV rapidly replicated in and selectively killed a variety of human tumor cell lines even in the presence of doses of interferon that completely protected normal human primary cell cultures. A single intratumoral injection of VSV was effective in reducing the tumor burden of nude mice bearing subcutaneous human melanoma xenografts. Our results support the use of VSV as a replication-competent oncolytic virus and demonstrate a new strategy for the treatment of interferon non-responsive tumors.

Cite this article

Stojdl, D., Lichty, B., Knowles, S. et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6, 821–825 (2000). https://doi.org/10.1038/77558

View full text

>> Full Text:   Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic viru